A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injection in the treatment of lower limb spasticity in adult subjects with spastic hemiparesis due to stroke or traumatic brain injury
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Ipsen
- 27 Apr 2018 Results from NCT01249404 and the extension study NCT01251367, presented at the 70th Annual Meeting of the American Academy of Neurology
- 23 Apr 2018 According to an Ipsen Biopharmaceuticals media release, data from this study will be presented at the American Academy of Neurology (AAN) 2018.
- 23 Apr 2018 Results presented in an Ipsen Biopharmaceuticals media release.